Atrium Therapeutics ($RNA) Insider Trading & Smart Money Activity

Atrium Therapeutics, Inc. · Biotechnology · Latest filing Jun 18, 2026

Atrium Therapeutics, Inc. ($RNA) has 4 13F position changes and 1 analyst rating on file.

Insider buyers (12 mo): 0
Insider sellers (12 mo): 0
Net insider $ (12 mo): $0
Congress trades (12 mo): 0
13F moves on file: 4
Analyst ratings on file: 1

RNA insider buying and selling by quarter

Quarter	Congress buys / sales	13F added / cut
Q1 2026	0 / 0	0 / 2
Q2 2026	0 / 0	0 / 2
Q3 2026	0 / 0	0 / 0
Q4 2026	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All RNA insider, congress, 13F and analyst activity

Date	Source	Who	Action	Shares	Value / amount	1W	1M	Story
Jun 18, 2026	Analyst	Cantor Fitzgerald	Reiterates to buy		PT $25	+0.9%	-7.1%	Read
May 15, 2026	13F	Pentwater Capital Management	Reduced	-5.42M sh	$7.45M	-1.1%	-3.6%	—
May 15, 2026	13F	Pentwater Capital Management	Reduced	-5.42M sh	$8.11M	-1.1%	-3.6%	Read
Feb 17, 2026	13F	Avoro Capital Advisors	Sold out	-7.64M sh				Read
Feb 17, 2026	13F	Avoro Capital Advisors	Sold out	-7.64M sh				Read

1W / 1M / 6M = how RNA moved from the trade or filing date.

Institutions moving RNA (13F)

Analyst ratings on RNA

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Jun 18, 2026	Cantor Fitzgerald	Reiterates	buy	$25	+0.9%	-7.1%		Read

Frequently asked questions

Which institutions changed their RNA positions?

Recent 13F filers moving the stock include Pentwater Capital Management and Avoro Capital Advisors.

Other biotechnology stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text